Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
1.
Arch. Clin. Psychiatry (Impr.) ; 46(4): 85-88, July-Aug. 2019. tab
Article in English | LILACS | ID: biblio-1019344

ABSTRACT

Abstract Background Impact of illness may vary with the medication adherence which in turn may vary with the attitude towards drugs. There is a paucity of research examining relationships between these variables. Objective To study the levels of drug attitude, adherence and its relationship with the impact of illness. Methods A total of 279 participants with mental illness in remission were assessed with socio-demographic and clinical proforma, scales like Hogan Drug Attitude Inventory (DAI), Impact of Illness Scale (IIS), and Morisky Medication Adherence Scale (MMAS) were used. Result Mean score on DAI, IIS, and MMAS were 2.38 (SD = 4.6), 25.88 (SD = 6.6), and 5.04 (SD = 2.2) respectively. On linear regression analysis (R2 = .122, DF = 2, F = 17.598, p < .001) IIS Score was statistically significant but negatively associated with the score of MMAS (p < .05) and DAI (p < .05). Discussion Impact of illness has an inverse relationship with the level of drug attitude and medication adherence. Improving drug attitude and adherence may buffer the impact of illness.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Medication Adherence/psychology , Mental Disorders/drug therapy , Cross-Sectional Studies , Sickness Impact Profile , Disease-Free Survival , India
2.
Arch. Clin. Psychiatry (Impr.) ; 43(3): 51-55, May.-June 2016. tab
Article in English | LILACS-Express | LILACS | ID: lil-789533

ABSTRACT

Abstract Background Paranormal beliefs are common among patients with mental illness. Such beliefs may mediate conceptualization of illness, treatment satisfaction and medication adherence. Objective To study the level of paranormal beliefs and its relationship with explanatory models, treatment adherence and satisfaction using standardized assessment tool. Methods Eighty nine patients with mental illness in remission were assessed with Sociodemographic proforma, Revised Paranormal Belief Scale (RPBS), Mental Distress Explanatory Model Questionnaire (MMAS), Morisky Medication Adherence Scale (MMAS) and Short Assessment of Patient Satisfaction (SAPS). Results Results revealed a high level of paranormal beliefs on RPBS (Mean 83.96, SD ± 23.91). Variables that had a statistically significant group difference on the score of RPBS were domicile status (p < 05), diagnosis (p < 001), method of treatment sought before (p < 001). In a linear regression analysis four variables explained 35.4% of the variance (R2 = .38, R2Adjusted = .35, F = 13.04, p < .001) in RPBS Score. These variables were total score of MDEMQ (Beta = .308, t = 3.435, p < .001), total score of MMAS (beta = .357, t = 3. 716, p < .001) and magico-religious treatment received earlier (beta = .306, t = 3.52, p < .001) and SAPS. Discussion Based on the finding of this study, it may be concluded that the level of paranormal beliefs may vary with some demographic variables. Levels of paranormal beliefs is positively associated with explanatory models and adherence in patients with mental illness in remission.

3.
Clinical Psychopharmacology and Neuroscience ; : 321-323, 2015.
Article in English | WPRIM | ID: wpr-209618

ABSTRACT

Atomoxetine, a selective norepinephrine inhibitor, is effective in comorbid anxiety and attention deficit hyperactivity disorder, however its role in panic disorder is unknown. We are presenting a case of panic disorder, who initially partially responded to clonazepam. When clonazepam was added with sertraline, escitalopram, desvenlafaxin, she did not improve significantly until paroxetine was added. When clonazepam-paroxetine combination was added with propranolol, etizolam, olanzepine, risperidone and amisulpride the symptom remission did not occur until a trial of Atomoxetine was done.


Subject(s)
Anxiety , Attention Deficit Disorder with Hyperactivity , Citalopram , Clonazepam , Norepinephrine , Panic Disorder , Panic , Paroxetine , Propranolol , Risperidone , Sertraline , Atomoxetine Hydrochloride
4.
Clinical Psychopharmacology and Neuroscience ; : 215-217, 2015.
Article in English | WPRIM | ID: wpr-121253

ABSTRACT

We are reporting a case of zolpidem induced multimodal hallucinations in a 22 year old female without any history of psychiatric disorders. Zolpidem, by acting on gamma-amino butyric acid type A receptor has a potential to cause a paradoxical reaction and there also exists a possibility of an induced delirium with its use. This case reports evaluates its potential to cause multimodal hallucinations. Zolpidem needs to be prescribed judiciously with the caution of potential side effects particularly in females.


Subject(s)
Female , Humans , Butyric Acid , Delirium , Hallucinations , Sleep Initiation and Maintenance Disorders
SELECTION OF CITATIONS
SEARCH DETAIL